A Systematic Review of Time and Resource Use Costs of Subcutaneous Versus Intravenous Administration of Oncology Biologics in a Hospital Setting
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A Systematic Review of Time and Resource Use Costs of Subcutaneous Versus Intravenous Administration of Oncology Biologics in a Hospital Setting
Authors
Keywords
-
Journal
Pharmacoeconomics-Open
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-08-23
DOI
10.1007/s41669-022-00361-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Flexible care in breast cancer
- (2021) A. Wardley et al. ESMO Open
- Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety study
- (2021) Sherko Kuemmel et al. BREAST CANCER RESEARCH AND TREATMENT
- Is weight-based IV dosing of trastuzumab preferable to SC fixed-dose in some patients? A systematic scoping review
- (2021) Hans-Christian Kolberg et al. BREAST
- Mortality in adult patients with solid or hematological malignancies and SARS-CoV-2 infection with a specific focus on lung and breast cancers: A systematic review and meta-analysis
- (2021) Marco Tagliamento et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study
- (2021) Joyce O'Shaughnessy et al. EUROPEAN JOURNAL OF CANCER
- Cost-minimization analysis of subcutaneous versus intravenous trastuzumab administration in Chilean patients with HER2-positive early breast cancer
- (2020) Luis Rojas et al. PLoS One
- Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study
- (2020) Sandra M Swain et al. LANCET ONCOLOGY
- The challenge of sustainability in healthcare systems: economic and organizational impact of subcutaneous formulations for rituximab and trastuzumab in onco-hematology
- (2020) Mattia Altini et al. Expert Review of Pharmacoeconomics & Outcomes Research
- The Changing Paradigm for the Treatment of HER2-Positive Breast Cancer
- (2020) Aena Patel et al. Cancers
- 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)†
- (2020) F. Cardoso et al. ANNALS OF ONCOLOGY
- Interferon-α versus interleukin-2 in Chinese patients with malignant melanoma
- (2019) Shenglong Li et al. ANTI-CANCER DRUGS
- Economic benefits of subcutaneous trastuzumab administration: A single institutional study from Karolinska University Hospital in Sweden
- (2019) Elham Hedayati et al. PLoS One
- Cost Minimization Analysis of Intravenous or Subcutaneous Trastuzumab Treatment in Patients With HER2-Positive Breast Cancer in Ireland
- (2019) Gary L. O'Brien et al. Clinical Breast Cancer
- Cost and time savings of subcutaneous trastuzumab (SC-T) in a public health system in Mexico.
- (2019) Cynthia Villarreal-Garza et al. JOURNAL OF CLINICAL ONCOLOGY
- Subcutaneous vs Intravenous Trastuzumab for Patients With ERBB2-Positive Early Breast Cancer
- (2019) Christian Jackisch et al. JAMA Oncology
- Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
- (2019) F Cardoso et al. ANNALS OF ONCOLOGY
- Humanistic and economic impact of subcutaneous versus intravenous administration of oncology biologics
- (2019) Kenneth C Anderson et al. Future Oncology
- PCN72 COMPARATIVE COST ANALYSIS OF SUBCUTANEOUS TRASTUZUMAB ORIGINATOR (HERCEPTIN®) VS INTRAVENOUS TRASTUZUMAB BIOSIMILAR (KANJINTI) FROM A HOSPITAL PERSPECTIVE IN ITALY
- (2019) A. D'Arpino et al. VALUE IN HEALTH
- Predictor Factors of Perceived Health in Family Caregivers of People Diagnosed with Mild or Moderate Alzheimer’s Disease
- (2019) María Dolores Ruiz-Fernández et al. International Journal of Environmental Research and Public Health
- Potential cost savings owing to the route of administration of oncology drugs
- (2018) Margreet G. Franken et al. ANTI-CANCER DRUGS
- Abstract P4-12-13: Comparative analysis of costs between subcutaneous formulation of trastuzumab versus intravenous formulation from the perspective of the Instituto Oncológico Nacional of Panamá from January to December 2016
- (2018) C Martin et al. CANCER RESEARCH
- Abstract PD3-11: Efficacy and safety of subcutaneous or intravenous trastuzumab in patients with HER2-positive early breast cancer after 5 years' treatment-free follow-up: Final analysis from the phase III, open-label, randomized HannaH study
- (2018) C Jackisch et al. CANCER RESEARCH
- Cost-effectiveness of Daratumumab-based Triplet Therapies in Patients With Relapsed or Refractory Multiple Myeloma
- (2018) Tian-tian Zhang et al. CLINICAL THERAPEUTICS
- Subcutaneous trastuzumab (Herceptin) versus intravenous trastuzumab for the treatment of patients with HER2-positive breast cancer: A time, motion and cost assessment study in a lean operating day care oncology unit
- (2018) Wiebren A.A. Tjalma et al. European Journal of Obstetrics & Gynecology and Reproductive Biology
- Impacts Of Time Spent On Rituximab Infusion On Patient Satisfaction, Stress, Employment, And Caregiver Burden
- (2018) MD Fisher et al. VALUE IN HEALTH
- Costs of subcutaneous and intravenous administration of trastuzumab for patients with HER2-positive breast cancer
- (2018) Jens Olsen et al. Journal of Comparative Effectiveness Research
- A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in the United States of America
- (2018) Noopur Raje et al. JOURNAL OF MEDICAL ECONOMICS
- Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities
- (2018) Beate Bittner et al. BIODRUGS
- Bénéfices médicoéconomiques des formes sous-cutanées de trastuzumab et de rituximab en hospitalisation de jour (étude SCuBA)
- (2018) Mireille Favier et al. BULLETIN DU CANCER
- Evaluation of subcutaneous rituximab administration on Canadian systemic therapy suites
- (2018) D. A. Stewart et al. Current Oncology
- Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
- (2018) Gunter von Minckwitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- PCN80 - BUDGET IMPACT ANALYSIS WITH USE OF SUBCUTANEUS TRASTUZUMAB
- (2018) J.E. Poquet-Jornet et al. VALUE IN HEALTH
- PMU26 - BUDGET IMPACT ANALYSIS OF INTRAVENOUS BIOSIMILARS COMPARED WITH INTRAVENOUS ORIGINATORS AND SUBCUTANEOUS PRODUCTS
- (2018) Y Jang et al. VALUE IN HEALTH
- PCN95 - A MULTICENTRIC EVALUATION OF CONSUMABLES AND TRANSPORTS COST OF BREAST CANCER PATIENT’S TREATED BY TRASTUZUMAB ACCORDING TO THE ADMINISTRATION FORM (IV VERSUS SC)
- (2018) C. Blein et al. VALUE IN HEALTH
- PCN75 - BUDGET IMPACT MODEL OF SUBCUTANEOUS TRASTUZUMAB COMPARED WITH INTRAVENOUS TRASTUZUMAB ON THE TREATMENT OF HER-2 POSITIVE BREAST CANCER IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM
- (2018) D. Kashiura et al. VALUE IN HEALTH
- PCN103 - PREDICTED TREATMENT COSTS AND SAVINGS PER PATIENT OF KANJINTI® (TRASTUZUMAB BIOSIMILAR) VS. SUBCUTANEOUS (SC) AND INTRAVENOUS (IV) HERCEPTIN® AND OTHER TRASTUZUMAB BIOSIMILARS IN ITALY
- (2018) I. Agirrezabal et al. VALUE IN HEALTH
- PCN67 - BUDGET IMPACT MODEL OF SUBCUTANEOUS RITUXIMAB COMPARED WITH INTRAVENOUS RITUXIMAB ON THE TREATMENT OF CD-20 POSITIVE NON-HODGKIN LYMPHOMA IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM
- (2018) D. Kashiura et al. VALUE IN HEALTH
- PCN93 - ECONOMIC MODELING FOR THE US OF INTRAVENOUS VS SUBCUTANEOUS RITUXIMAB IN NON-HODGKIN’S LYMPHOMA TREATED WITH R-CHOP
- (2018) A. McBride et al. VALUE IN HEALTH
- Behind the subcutaneous trastuzumab hype: evaluation of benefits and their transferability to Central Eastern European countries
- (2018) András Inotai et al. Expert Review of Pharmacoeconomics & Outcomes Research
- Patients' preference of trastuzumab administration (subcutaneous versus intravenous) in HER2-positive metastatic breast cancer: Results of the randomised MetaspHer study
- (2017) X. Pivot et al. EUROPEAN JOURNAL OF CANCER
- Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study
- (2017) Pieternella Lugtenburg et al. HAEMATOLOGICA
- Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
- (2017) Gunter von Minckwitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- An observational time and motion study of denosumab subcutaneous injection and zoledronic acid intravenous infusion in patients with metastatic bone disease: results from three European countries
- (2017) Jean-Jacques Body et al. SUPPORTIVE CARE IN CANCER
- Subcutaneous vs Intravenous Administration of Trastuzumab in Her2+ Breast Cancer Patients: A Montenegrin Cost-Minimization Analysis
- (2017) V Todorovic et al. VALUE IN HEALTH
- To Determine The Financial Imapct of Introducing Sc Rituximab (MABTHERA) vs. Currently used iv rituximab (MABTHERA) on The Budgets of Different Hospitals Across The Kingdom of Saudi Arabia (KSA)
- (2017) M Rauf et al. VALUE IN HEALTH
- Financial Impact of Introducing Sc Trastuzumab (HERCEPTIN) Versus Currently Used IV Trastuzumab (HERCEPTIN) on The Budgets of Different Hospitals Across Kingdom of Saudi Arabia (KSA)
- (2017) N A et al. VALUE IN HEALTH
- Resource utilization and cost saving analysis of subcutaneous versus intravenous trastuzumab in early breast cancer patients
- (2017) Alberto Farolfi et al. Oncotarget
- Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study
- (2017) Pieternella Lugtenburg et al. HAEMATOLOGICA
- Cost-effectiveness of denosumab versus zoledronic acid for preventing skeletal-related events in the Czech Republic
- (2017) Joaquim Cristino et al. JOURNAL OF MEDICAL ECONOMICS
- Societal cost of subcutaneous and intravenous trastuzumab for HER2-positive breast cancer – An observational study prospectively recording resource utilization in a Swedish healthcare setting
- (2016) Sara Olofsson et al. BREAST
- 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial
- (2016) Luca Gianni et al. LANCET ONCOLOGY
- A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2-positive early breast cancer
- (2016) Erwin De Cock et al. Cancer Medicine
- Time Savings with Rituximab Subcutaneous Injection versus Rituximab Intravenous Infusion: A Time and Motion Study in Eight Countries
- (2016) Erwin De Cock et al. PLoS One
- Implications of subcutaneous or intravenous delivery of trastuzumab; further insight from patient interviews in the PrefHer study
- (2015) L. Fallowfield et al. BREAST
- Subcutaneous Trastuzumab for HER2-positive Breast Cancer – Evidence and Practical Experience in 7 German Centers
- (2015) C. Jackisch et al. GEBURTSHILFE UND FRAUENHEILKUNDE
- Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
- (2015) Sandra M. Swain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pharmacoeconomic Evaluation Of The Use Of Trastuzumab For Subcutaneous Administration Compared To Intravenous Dosage Form In The Treatment Of Breast Cancer
- (2015) A Kulikov et al. VALUE IN HEALTH
- Subcutaneous Vs Intravenous Administration Of Trastuzumab In Her2+ Breast Cancer Patients: A Macedonian Cost-Minimization Analysis
- (2015) A Nestorovska et al. VALUE IN HEALTH
- Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH study
- (2014) C. Jackisch et al. ANNALS OF ONCOLOGY
- Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study
- (2014) X. Pivot et al. ANNALS OF ONCOLOGY
- Subcutaneous Administration of Monoclonal Antibodies in Oncology
- (2014) C. Jackisch et al. GEBURTSHILFE UND FRAUENHEILKUNDE
- Time Savings With Transtuzumab Subcutaneous (SC) Injection Verse Trastuzumab Intravenous (IV) Infusion: A Time and Motion Study in 3 Russian Centers
- (2014) E. De Cock et al. VALUE IN HEALTH
- Cost-Minimization Analysis of Trastuzumab Intravenous Versus Trastuzumab Subcutaneous for the Treatment of Patients With HER2+ Early Breast Cancer And Metastatic Breast Cancer in Greece
- (2014) C. Mylonas et al. VALUE IN HEALTH
- Subcutaneous vs intravenous rituximab in patients with non-Hodgkin lymphoma: a time and motion study in the United Kingdom
- (2014) Simon Rule et al. JOURNAL OF MEDICAL ECONOMICS
- Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study
- (2013) Sandra M Swain et al. LANCET ONCOLOGY
- Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study
- (2013) Xavier Pivot et al. LANCET ONCOLOGY
- Hospital Resources Consumption Associated with Trastuzumab Treatment in Breast Cancer in Portugal
- (2013) S. Andrade et al. VALUE IN HEALTH
- Systematic Review of Drug Administration Costs and Implications for Biopharmaceutical Manufacturing
- (2013) Ebenezer Tetteh et al. Applied Health Economics and Health Policy
- Comparison of Subcutaneous and Intravenous Administration of Trastuzumab: A Phase I/Ib Trial in Healthy Male Volunteers and Patients With HER2-Positive Breast Cancer
- (2012) Chris Wynne et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial
- (2012) Gustavo Ismael et al. LANCET ONCOLOGY
- Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States
- (2012) Alison Stopeck et al. JOURNAL OF MEDICAL ECONOMICS
- Adjuvant Trastuzumab in HER2-Positive Breast Cancer
- (2011) Dennis Slamon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort
- (2010) Luca Gianni et al. LANCET
- Catheter-Associated Thrombosis in Patients With Malignancy
- (2009) Sudeep P. Shivakumar et al. JOURNAL OF CLINICAL ONCOLOGY
- Methodological Considerations in Cost of Prostate Cancer Studies: A Systematic Review
- (2008) Laurent Molinier et al. VALUE IN HEALTH
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now